Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias - Wikidata - awgldk - TriplyDB

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

http://www.wikidata.org/entity/Q36667434

about

Therapeutic Implications of Targeting AKT Signaling in Melanoma Targeting RTK Signaling Pathways in Cancer Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 Absence of AKT1 mutations in glioblastoma.High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.Identifying subtype-specific associations between gene expression and DNA methylation profiles in breast cancer The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Regulation of Akt signaling activation by ubiquitination.Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.K63-linked ubiquitination in kinase activation and cancer.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.Mutant AKT1-E17K is oncogenic in lung epithelial cells The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.A novel AKT3 mutation in melanoma tumours and cell lines Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Systematic morphological profiling of human gene and allele function via Cell Painting.Potential role of PI3K inhibitors in the treatment of breast cancer.Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.Molecular oncology of lung cancer.Targeting the PI3K signaling pathway in cancer therapy.Targeting the PI3K pathway for cancer therapy.EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.AKT Inhibition in Solid Tumors With AKT1 Mutations.AKT in cancer: new molecular insights and advances in drug development.Genetic landscape of meningioma.Targeting protein kinase-b3 (akt3) signaling in melanoma.

P2860

Q24631438-047F02F7-69F1-432B-ACAA-D17FA4A3AF08 Q26781278-CDA73E4B-E1C1-4949-9579-FB5262F12BC3 Q28533515-C7E1FAC8-72CB-4ADA-97BD-4E03CECD86E4 Q28541288-3A740271-998F-416A-BCF0-B1C09C41FA8D Q28550038-C3F2384A-EFEF-429C-9F69-AAA15BA06D3A Q28550300-D6879EEB-C99E-4A40-83D4-838DFB4AA520 Q30439629-E7CE5DEB-1F6E-4B59-9EFC-69AE244F5DE4 Q33515565-E86D9AEA-5276-482F-844F-2EA25D2B0200 Q33610437-3AFF2311-74A4-49A6-98A1-2B922E4D7D6F Q33637346-5586AAD7-8E1F-49E2-88CB-A0623F2F32B4 Q33771056-6A4456C5-B3D5-4962-9BC2-0E67B99FF21C Q34286759-A09549D3-A848-4928-835F-E1AA7A99908A Q34586019-9FE0F721-8258-4119-B336-28F2CD88D473 Q34592027-E18E0633-40EE-40B6-AE87-8DC91EA61F53 Q34616536-39B4B40D-273B-474D-9ACB-321E9AE1FCFE Q34799443-075F226A-96B9-4E77-9F3B-DB15FF3C58AE Q35691075-FFE36A48-2F2F-43FB-9735-2A5F9C6B9A15 Q35735954-C5677A37-DFF7-4B26-A4FE-443225D3B122 Q35820044-84E8D504-5B49-42E4-8DC0-F89FF884ED2C Q35971438-AEA779B9-2475-4E8E-8570-6B48F7FBC83D Q36101969-640BFAF3-8213-40CF-8F34-04C3ECFD0E6D Q36545440-7492E33E-7DBE-4DC6-9BD5-38ACB679CB7F Q36858031-84DF38FA-BE3D-4C91-A1AB-BCFAACC5B336 Q36939659-98476B99-4EA8-419F-8559-C551F0C68521 Q36944047-B56FED82-CF39-45BD-877A-566B607DF920 Q37131339-6B7BCB2C-024E-40FE-8081-12E2EE6FDAE2 Q37269747-4B4CB6C3-BDC0-4E5C-BE8B-943F7CA989EC Q37692104-766AFD7F-740B-4409-82A1-670D62BFDD05 Q37745645-6A629FB8-CF18-4157-960A-FD9BFFE6E18A Q37783617-9655B6FD-6E23-4016-9622-CCEFBDBB9571 Q37872655-79505E7A-6F70-4719-874E-308ED42ABF5C Q37919395-B6B55E87-1A92-4F46-8000-6F623AA0371E Q37975242-1EEE85E8-0329-4821-8E3D-4212B21A2B9A Q38019609-F270481C-C97D-4D0E-98F1-7C20FF14B84D Q38034817-53EAE595-8413-4496-B916-818EA81F7098 Q38242086-ED6B3382-0B70-47A0-9702-A23CE7EC94FD Q38794254-9A80E479-D43E-48F5-B7F4-6AC4D000D812 Q38846044-44CEA515-AAA6-4F54-92CC-A2881E8B9F6B Q38953562-ED01C606-AC0B-409F-86B8-22D9FC957A46 Q39074281-21059371-822B-4195-8918-B0E5DEC5F522

P2860

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

http://www.wikidata.org/entity/Q36667434

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@ast

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@en

type

label

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@ast

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@en

prefLabel

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@ast

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@en

P1433

Q36667434-8855B9B7-E3CC-4956-9D0D-62FEDA800820

P1476

Q36667434-5D9B67D7-6D5C-4551-817F-D812D9DFCAC4

P2093

Q36667434-60197522-0469-4671-8D5C-30A4508F653E

Q36667434-7B567E0E-00E6-41E6-A069-6AE16054E41E

Q36667434-C99D106E-F103-42ED-BB34-417745FC1799

Q36667434-DB1387C7-A132-4CCA-8055-FBA84539069A

P2860

Q36667434-026BED71-F2CF-48CB-ADFE-3BD41A94E90C

Q36667434-1CF7B8AD-DEB1-4F1D-91F3-0522DD5E85ED

Q36667434-2B0D280E-396B-4BA9-902C-AF66C6389183

Q36667434-2EB16EFE-A4B8-4F07-997C-D5E91C40A644

Q36667434-384C7EA6-56DC-442C-8686-60FAC69B743F

Q36667434-3DAC9246-E512-4499-81F4-47235FF9F803

Q36667434-45C5BED3-F4C9-43AA-8F36-5996C41F6F99

Q36667434-5B9DF475-AFCF-4A3D-A16C-640413631C4C

Q36667434-62269DFF-8E47-4AD3-8607-B88F7C547C13

Q36667434-7AA01B0E-CC24-4B9E-8A9D-A65AB330AB05

P2888

Q36667434-5C8526FA-C866-4318-9458-0276A48FC0A9

P304

Q36667434-A8EE078F-CEAF-4F01-98FF-BF3620FC6E27

P31

Q36667434-35EB880E-C75F-499F-A69C-2D3B8FC5415B

P356

Q36667434-A9DB804A-7066-4081-BE0D-C7F017790FE4

P407

Q36667434-2D5C7745-F42D-45E4-9EDC-F9C220BC9BF7

P433

Q36667434-A3C449B1-1A32-4E1E-A0D1-ABE22F2DB054

P478

Q36667434-9E9BE05F-7E16-4E97-83B4-D999A572D706

P577

Q36667434-9E08A5DC-F131-4AD8-8247-257B04A7FDD8

P5875

Q36667434-4DC3ED44-0712-4B72-952E-72EBA0463146

P6179

Q36667434-65764002-1EFA-4685-9068-F46E6954C4AE

P698

Q36667434-D93D8595-7A3A-4903-B33A-30EDD3F41C94

P921

Q36667434-4D2C671B-CC89-4C21-87E0-4986440B4301

P932

Q36667434-DF1B6A8A-E6C8-4AE0-8B7E-0E394AAF1846

P356

P1433

British Journal of Cancer

P1476

Mutational analysis of oncogen ...... d cancers and acute leukaemias

@en

P2093

E G Jeong

http://www.w3.org/2001/XMLSchema#string

M S Kim

http://www.w3.org/2001/XMLSchema#string

N J Yoo

http://www.w3.org/2001/XMLSchema#string

S H Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

High frequency of mutations of the PIK3CA gene in human cancers

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

AKT plays a central role in tumorigenesis.

Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Tyrosine kinase-dependent, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase-independent signaling pathways prevent lung adenocarcinoma cells from anoikis.

P2888

P304

1533-1535

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604212

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5460625

http://www.w3.org/2001/XMLSchema#string

P6179

1049947560

http://www.w3.org/2001/XMLSchema#string

P698

18392055

http://www.w3.org/2001/XMLSchema#string

P921

P932

2391109

http://www.w3.org/2001/XMLSchema#string